Konstantinos Marmagkiolis
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Konstantinos Marmagkiolis has a total of 195 co-authors. Here are the top co-authors by number of shared publications:
- Cezar Iliescu
University of Texas MD Anderson Cancer Center
29 shared publications Mehmet Cilingiroglu
University of Hawaii Foundation Honolulu Hawaii USA
27 shared publications- Mehmet Cilingiroglu
University of Hawai'i at Manoa John A Burns School of Medicine, San Diego, CA, United States of America
26 shared publications - Dominique J. Monlezun
Division of Hospital Internal Medicine, Mayo Clinic, Rochester, MN, USA
13 shared publications - Kevin A. Honan
The University of Texas Health Science Center at Houston, United States
11 shared publications - Mehmet Cilingiroglu
Arkansas Heart Hospital, Little Rock, AR
11 shared publications
Latest Publications
- 30 October 2026
- Published by Wiley in Catheterization and Cardiovascular Interventions
IVUS‐Guided Dobutamine Challenge to Guide Anomalous RCA PCI: An Interesting Case Report
Congenital coronary artery anomalies are quite uncommon—they are observed in 1.3% of the coronary angiograms. Although most of them are benign, some coronary anomalies are associated with poor clinical outcomes. The exact mechanism of these outcomes in patients with anomalous RCA from the left aortic cusp with interarterial course is hypothesized to be either compression of the coronary artery during its course between the aorta and the pulmonary artery, or obstruction of the coronary flow during exercise due to the acute angulation of the RCA ostium. We present the case of a 54 y/o patient with NSTEMI, who, after a diagnostic coronary angiogram and coronary CT, was found to have complex coronary artery disease, including an anomalous RCA from the left aortic cusp with “malignant” interarterial course. In order to determine the optimal treatment, we proceeded with IVUS assessment of the ostial and proximal RCA with dobutamine challenge, which showed significant stenosis of both the RCA ostium and the interarterial segment at the peak dose of the dobutamine challenge. As a result a decision was made to treat both the RCA ostium and its interarterial segment with PCI, producing an excellent final result. Our case underscores the importance of the combination of IVUS and dobutamine challenge in order to answer the ever‐important pathophysiologic mechanism of a lesion and accordingly provide tailor‐made treatment for anomalous coronary arteries.
- 30 October 2026
- Published by Wiley in Catheterization and Cardiovascular Interventions
IVUS‐Guided Dobutamine Challenge to Guide Anomalous RCA PCI: An Interesting Case Report
Congenital coronary artery anomalies are quite uncommon—they are observed in 1.3% of the coronary angiograms. Although most of them are benign, some coronary anomalies are associated with poor clinical outcomes. The exact mechanism of these outcomes in patients with anomalous RCA from the left aortic cusp with interarterial course is hypothesized to be either compression of the coronary artery during its course between the aorta and the pulmonary artery, or obstruction of the coronary flow during exercise due to the acute angulation of the RCA ostium. We present the case of a 54 y/o patient with NSTEMI, who, after a diagnostic coronary angiogram and coronary CT, was found to have complex coronary artery disease, including an anomalous RCA from the left aortic cusp with “malignant” interarterial course. In order to determine the optimal treatment, we proceeded with IVUS assessment of the ostial and proximal RCA with dobutamine challenge, which showed significant stenosis of both the RCA ostium and the interarterial segment at the peak dose of the dobutamine challenge. As a result a decision was made to treat both the RCA ostium and its interarterial segment with PCI, producing an excellent final result. Our case underscores the importance of the combination of IVUS and dobutamine challenge in order to answer the ever‐important pathophysiologic mechanism of a lesion and accordingly provide tailor‐made treatment for anomalous coronary arteries.
- Open Access
- 2 May 2025
- Published by Elsevier in Journal of the Society for Cardiovascular Angiography & Interventions
- Vol. 4 (6) , 103659
Cardio-oncology Outcomes in Ultrasound-assisted Versus Standard Catheter-directed Thrombolysis for Acute Pulmonary Embolus
- 2 May 2025
- Published by Elsevier in Journal of the Society for Cardiovascular Angiography & Interventions
- Vol. 4 (6) , 103659
Open AccessCardio-oncology Outcomes in Ultrasound-assisted Versus Standard Catheter-directed Thrombolysis for Acute Pulmonary Embolus
- 5 February 2025
- Published by Wiley in Catheterization and Cardiovascular Interventions
Structural Heart Disease Interventions. Year in Review 2023–2024
In 2023–2024, there was a surge in research on structural heart disease. This review aims to provide a comprehensive overview of the field for both general and interventional cardiologists, especially those with a keen interest in structural heart interventions. It summarizes the most important randomized controlled trials, meta‐analyses, retrospective analyses, data registries, and noteworthy late‐breaking studies unveiled at prominent cardiology conferences.
- 5 February 2025
- Published by Wiley in Catheterization and Cardiovascular Interventions
Structural Heart Disease Interventions. Year in Review 2023–2024
In 2023–2024, there was a surge in research on structural heart disease. This review aims to provide a comprehensive overview of the field for both general and interventional cardiologists, especially those with a keen interest in structural heart interventions. It summarizes the most important randomized controlled trials, meta‐analyses, retrospective analyses, data registries, and noteworthy late‐breaking studies unveiled at prominent cardiology conferences.
- Open Access
- 13 November 2024
- Published by Radcliffe Medical Media Ltd in US Cardiology Review
- Vol. 18
Successful Percutaneous Transcatheter Aortic Valve Replacement for Severe Aortic Regurgitation in a High-risk Patient with Cardiorenal Syndrome
The absence of a Food and Drug Administration-approved percutaneous valve technology for the treatment of severe aortic regurgitation (AR) presents a challenge for high-risk patients. In this report, we describe the successful treatment of an 84-year-old male patient suffering from severe symptomatic AR and concomitant cardiorenal syndrome with renal failure using a 34-mm Evolut R (Medtronic) self-expanding transcatheter aortic valve replacement. This intervention resulted in the resolution of AR, cardiorenal syndrome, and congestive heart failure symptoms.
- 13 November 2024
- Published by Radcliffe Medical Media Ltd in US Cardiology Review
- Vol. 18
Open AccessSuccessful Percutaneous Transcatheter Aortic Valve Replacement for Severe Aortic Regurgitation in a High-risk Patient with Cardiorenal Syndrome
The absence of a Food and Drug Administration-approved percutaneous valve technology for the treatment of severe aortic regurgitation (AR) presents a challenge for high-risk patients. In this report, we describe the successful treatment of an 84-year-old male patient suffering from severe symptomatic AR and concomitant cardiorenal syndrome with renal failure using a 34-mm Evolut R (Medtronic) self-expanding transcatheter aortic valve replacement. This intervention resulted in the resolution of AR, cardiorenal syndrome, and congestive heart failure symptoms.
- 21 October 2022
- Published by HMP Communications, LLC in Journal of Invasive Cardiology
- Vol. 34 (11) , E784-E792
Superficial Femoral Artery Endovascular Therapy: 12-Month Primary Patency Rates of Contemporary Endovascular Devices from 25,051 Patients
The authors performed a literature search using. Published articles including endovascular interventions in the SFA with reported 12-month “primary patency” rates as endpoints were included.
- 21 October 2022
- Published by HMP Communications, LLC in Journal of Invasive Cardiology
- Vol. 34 (11) , E784-E792
Superficial Femoral Artery Endovascular Therapy: 12-Month Primary Patency Rates of Contemporary Endovascular Devices from 25,051 Patients
The authors performed a literature search using. Published articles including endovascular interventions in the SFA with reported 12-month “primary patency” rates as endpoints were included.
- 8 August 2022
- Published by Elsevier in Cardiovascular Revascularization Medicine
- Vol. 40, 118
The Effect of Transcatheter Tricuspid Valve Repair on Renal Functions
- 8 August 2022
- Published by Elsevier in Cardiovascular Revascularization Medicine
- Vol. 40, 118
The Effect of Transcatheter Tricuspid Valve Repair on Renal Functions
- Open Access
Reclassification of Treatment Strategy with Fractional Flow Reserve in Cancer Patients with Coronary Artery Disease
Background and Objectives: Cancer and coronary artery disease (CAD) often coexist. Compared to quantitative coronary angiography (QCA), fractional flow reserve (FFR) has emerged as a more reliable method of identifying significant coronary stenoses. We aimed to assess the specific management, safety and outcomes of FFR-guided percutaneous coronary intervention (PCI) in cancer patients with stable CAD. Materials and Methods: FFR was used to assess cancer patients that underwent coronary angiography for stable CAD between September 2008 and May 2016, and were found to have ≥50% stenosis by QCA. Patients with lesions with an FFR > 0.75 received medical therapy alone, while those with FFR ≤ 0.75 were revascularized. Procedure-related complications, all-cause mortality, nonfatal myocardial infarction, or urgent revascularizations were analyzed. Results: Fifty-seven patients with stable CAD underwent FFR on 57 lesions. Out of 31 patients with ≥70% stenosis as measured by QCA, 14 (45.1%) had an FFR ≥ 0.75 and lesions were reclassified as moderate and did not receive PCI nor DAPT. Out of 26 patients with p = 0.03). Conclusions: Further studies are needed to define the optimal therapeutic approach for cancer patients with CAD. Using an FFR cut-off point of 0.75 to guide PCI translates into fewer interventions and can facilitate cancer care. There was an overall reduction in mortality in patients that received a stent, suggesting increased resilience to cancer therapy and progression.
Open AccessReclassification of Treatment Strategy with Fractional Flow Reserve in Cancer Patients with Coronary Artery Disease
Background and Objectives: Cancer and coronary artery disease (CAD) often coexist. Compared to quantitative coronary angiography (QCA), fractional flow reserve (FFR) has emerged as a more reliable method of identifying significant coronary stenoses. We aimed to assess the specific management, safety and outcomes of FFR-guided percutaneous coronary intervention (PCI) in cancer patients with stable CAD. Materials and Methods: FFR was used to assess cancer patients that underwent coronary angiography for stable CAD between September 2008 and May 2016, and were found to have ≥50% stenosis by QCA. Patients with lesions with an FFR > 0.75 received medical therapy alone, while those with FFR ≤ 0.75 were revascularized. Procedure-related complications, all-cause mortality, nonfatal myocardial infarction, or urgent revascularizations were analyzed. Results: Fifty-seven patients with stable CAD underwent FFR on 57 lesions. Out of 31 patients with ≥70% stenosis as measured by QCA, 14 (45.1%) had an FFR ≥ 0.75 and lesions were reclassified as moderate and did not receive PCI nor DAPT. Out of 26 patients with p = 0.03). Conclusions: Further studies are needed to define the optimal therapeutic approach for cancer patients with CAD. Using an FFR cut-off point of 0.75 to guide PCI translates into fewer interventions and can facilitate cancer care. There was an overall reduction in mortality in patients that received a stent, suggesting increased resilience to cancer therapy and progression.
- Open Access
Fractional Flow Reserve Cardio-Oncology Effects on Inpatient Mortality, Length of Stay, and Cost Based on Malignancy Type: Machine Learning Supported Nationally Representative Case-Control Study of 30 Million Hospitalizations
Background and Objectives: There are no nationally representative studies of mortality and cost effectiveness for fractional flow reserve (FFR) guided percutaneous coronary interventions (PCI) in patients with cancer. Our study aims to show how this patient population may benefit from FFR-guided PCI. Materials and Methods: Propensity score matched analysis and backward propagation neural network machine learning supported multivariable regression was performed for inpatient mortality in this case-control study of the 2016 National Inpatient Sample (NIS). Regression results were adjusted for age, race, income, geographic region, metastases, mortality risk, and the likelihood of undergoing FFR versus non-FFR PCI. All analyses were adjusted for the complex survey design to produce nationally representative estimates. Results: Of the 30,195,722 hospitalized patients meeting criteria, 3.37% of the PCIs performed included FFR. In propensity score adjusted multivariable regression, FFR versus non-FFR PCI significantly reduced inpatient mortality (OR 0.47, 95%CI 0.35–0.63; p < 0.001) and length of stay (LOS) (in days; beta −0.23, 95%CI −0.37–−0.09; p = 0.001) while increasing cost (in USD; beta $5708.63, 95%CI, 3042.70–8374.57; p < 0.001), without significantly increasing complications overall. FFR versus non-FFR PCI did not specifically change cancer patients’ inpatient mortality, LOS, or cost. However, FFR versus non-FFR PCI significantly increased inpatient mortality for Hodgkin’s lymphoma (OR 52.48, 95%CI 7.16–384.53; p < 0.001) and rectal cancer (OR 24.38, 95%CI 2.24–265.73; p = 0.009). Conclusions: FFR-guided PCI may be safely utilized in patients with cancer as it does not significantly increase inpatient mortality, complications, and LOS. These findings support the need for an increased utilization of FFR-guided PCI and further studies to evaluate its long-term impact.
Open AccessFractional Flow Reserve Cardio-Oncology Effects on Inpatient Mortality, Length of Stay, and Cost Based on Malignancy Type: Machine Learning Supported Nationally Representative Case-Control Study of 30 Million Hospitalizations
Background and Objectives: There are no nationally representative studies of mortality and cost effectiveness for fractional flow reserve (FFR) guided percutaneous coronary interventions (PCI) in patients with cancer. Our study aims to show how this patient population may benefit from FFR-guided PCI. Materials and Methods: Propensity score matched analysis and backward propagation neural network machine learning supported multivariable regression was performed for inpatient mortality in this case-control study of the 2016 National Inpatient Sample (NIS). Regression results were adjusted for age, race, income, geographic region, metastases, mortality risk, and the likelihood of undergoing FFR versus non-FFR PCI. All analyses were adjusted for the complex survey design to produce nationally representative estimates. Results: Of the 30,195,722 hospitalized patients meeting criteria, 3.37% of the PCIs performed included FFR. In propensity score adjusted multivariable regression, FFR versus non-FFR PCI significantly reduced inpatient mortality (OR 0.47, 95%CI 0.35–0.63; p < 0.001) and length of stay (LOS) (in days; beta −0.23, 95%CI −0.37–−0.09; p = 0.001) while increasing cost (in USD; beta $5708.63, 95%CI, 3042.70–8374.57; p < 0.001), without significantly increasing complications overall. FFR versus non-FFR PCI did not specifically change cancer patients’ inpatient mortality, LOS, or cost. However, FFR versus non-FFR PCI significantly increased inpatient mortality for Hodgkin’s lymphoma (OR 52.48, 95%CI 7.16–384.53; p < 0.001) and rectal cancer (OR 24.38, 95%CI 2.24–265.73; p = 0.009). Conclusions: FFR-guided PCI may be safely utilized in patients with cancer as it does not significantly increase inpatient mortality, complications, and LOS. These findings support the need for an increased utilization of FFR-guided PCI and further studies to evaluate its long-term impact.
- 1 June 2022
- Published by HMP Communications, LLC in Journal of Invasive Cardiology
- Vol. 34 (6) , E481-E483
Single Radial Access Simultaneous Left Ventricular and Ascending Aortic Pressure for the Evaluation of Aortic Stenosis: The “Double-Barrel” Technique
The authors describe the first-in-man single radial access “double-barrel” technique for the evaluation of aortic stenosis.
- 1 June 2022
- Published by HMP Communications, LLC in Journal of Invasive Cardiology
- Vol. 34 (6) , E481-E483
Single Radial Access Simultaneous Left Ventricular and Ascending Aortic Pressure for the Evaluation of Aortic Stenosis: The “Double-Barrel” Technique
The authors describe the first-in-man single radial access “double-barrel” technique for the evaluation of aortic stenosis.